EMA Authorised: Mirvaso (brimonidine tartrate) — Galderma International

View source ↗

Summary

The European Medicines Agency authorised Mirvaso (brimonidine tartrate) for rosacea-related facial erythema. The marketing authorization holder is Galderma Inte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rosacea

Drugs mentioned

• Mirvaso (brimonidine tartrate)

Snippet

Status: Authorised. Therapeutic area: Skin Diseases. MAH: Galderma International. Decision date: 11/12/2024